Skip to main content

Table 1 Characteristics of 99 patients accepted for treatment by gene therapy as part of their disease management

From: Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial

Case information

Groupa

P-value

 

I (n = 35)

II (n = 33)

III (n = 31)

 

Age, years, mean ± SDb

57.06 ± 10.63

59.79 ± 12.31

55.29 ± 10.60

0.274

Gender, n (%)c

   

0.953

 Male

21 (60.0)

21 (63.6)

19 (61.3)

 

 Female

14 (40.0)

12 (36.4)

12 (38.7)

 

Tumor classification, n (%)d

   

0.909

 T2

3 (8.6)

3 (9.1)

4 (12.9)

 

 T3

16 (45.7)

13 (39.4)

12 (38.7)

 

 T4

16 (45.7)

17 (51.5)

15 (48.4)

 

UICC stage, n (%)d

   

0.0.996

 III

11 (31.4)

9 (27.3)

9 (29.0)

 

 IVa

20 (57.1)

20 (60.6)

19 (61.3)

 

 IVb

4 (11.4)

4 (12.1)

3 (9.7)

 

Tumor site, n (%)e

   

1.000

 Tongue

13 (37.1)

11 (33.3)

12 (38.7)

 

 Buccal membrane

10 (28.6)

10 (30.3)

8 (25.8)

 

 Gingiva

6 (17.1)

7 (21.2)

7 (22.6)

 

 Floor of mouth

3 (8.6)

2 (6.1)

2 (6.5)

 

 Palate

1 (2.9)

1 (3.0)

0 (0.0)

 

 Lips

2 (5.7)

2 (6.1)

2 (6.5)

 

Bax expression, n (%)e

   

0.796

 < 1% (-)

30 (85.7)

30 (90.9)

27 (87.1)

 

 10 to 25% (+)

5 (14.3)

3 (9.1)

4 (12.9)

 

Bcl-2 expression, n (%)d

   

0.241

 <10% (-)

2 (5.7)

5 (15.2)

5 (16.1)

 

 10 to 24% (+)

4 (11.4)

10 (30.3)

4 (12.9)

 

 25 to 49% (++)

15 (42.9)

9 (27.3)

13 (41.9)

 

 ≥50% (+++)

14 (40.0)

9 (27.3)

9 (29.0)

 

Tumor grading, n (%)d

   

0.956

 I

5 (14.3)

3 (9.1)

2 (6.5)

 

 II

14 (40.0)

15 (45.5)

15 (48.4)

 

 III

16 (45.7)

15 (45.5)

14 (45.2)

 
  1. aGroup I: chemotherapy and rAD-p53; group II: rAD-p53; group III: chemotherapy.
  2. P-values are based on bANOVA; cχ2; dKruskal-Wallis test, and eFisher’s exact test.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us